Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in combination with endocrine therapy for treatment of estrogen receptor-positive breast cancer.
The study will include patients with localized post-menopausal breast cancer with detectable circulating tumor DNA (ctDNA) after surgery, and will assess tumor response to ribociclib treatment in combination with endocrine therapy compared to endocrine therapy alone, the company said. The trial will use Natera's Signatera ctDNA test to identify eligible study participants.
